TY - JOUR
T1 - Evaluation of the clinical performance of noninvasive prenatal testing at a Japanese laboratory
AU - Japan N. I. P. T. Consortium
AU - Sasaki, Yuna
AU - Yamada, Takahiro
AU - Tanaka, Shiro
AU - Sekizawa, Akihiko
AU - Hirose, Tatsuko
AU - Suzumori, Nobuhiro
AU - Kaji, Takashi
AU - Kawaguchi, Satoshi
AU - Hasuo, Yasuyuki
AU - Nishizawa, Haruki
AU - Matsubara, Keiichi
AU - Hamanoue, Haruka
AU - Fukushima, Akimune
AU - Endo, Masayuki
AU - Yamaguchi, Masayuki
AU - Kamei, Yoshimasa
AU - Sawai, Hideaki
AU - Miura, Kiyonori
AU - Ogawa, Masaki
AU - Tairaku, Shinya
AU - Nakamura, Hiroaki
AU - Sanui, Ayako
AU - Mizuuchi, Masahito
AU - Okamoto, Yoko
AU - Kitagawa, Michihiro
AU - Kawano, Yukie
AU - Masuyama, Hisashi
AU - Murotsuki, Jun
AU - Osada, Hisao
AU - Kurashina, Ryuhei
AU - Samura, Osamu
AU - Ichikawa, Mayuko
AU - Sasaki, Rumi
AU - Maeda, Kazuhisa
AU - Kasai, Yasuyo
AU - Yamazaki, Tomomi
AU - Neki, Reiko
AU - Hamajima, Naoki
AU - Katagiri, Yukiko
AU - Izumi, Shunichiro
AU - Nakayama, Setsuko
AU - Miharu, Norio
AU - Yokohama, Yuko
AU - Hirose, Masaya
AU - Kawakami, Kosuke
AU - Ichizuka, Kiyotake
AU - Sase, Masakatsu
AU - Sugimoto, Kohei
AU - Nagamatsu, Takeshi
AU - Shiga, Tomomi
N1 - Publisher Copyright:
© 2021 Japan Society of Obstetrics and Gynecology.
PY - 2021/10
Y1 - 2021/10
N2 - Aim: We aimed to evaluate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of noninvasive prenatal testing (NIPT) in high-risk pregnant women. Methods: Pregnant women who underwent GeneTech NIPT, the most commonly used NIPT in Japan, between January 2015 and March 2019, at Japan NIPT Consortium medical sites were recruited for this study. The exclusion criteria were as follows: pregnant women with missing survey items, multiple pregnancy/vanishing twins, chromosomal abnormalities in the fetus other than the NIPT target disease, and nonreportable NIPT results. Sensitivity and specificity were calculated from the obtained data, and maternal age-specific PPV and NPV were estimated. Results: Of the 45 504 cases, 44 263 cases fulfilling the study criteria were included. The mean maternal age and gestational weeks at the time of procedure were 38.5 years and 13.1 weeks, respectively. Sensitivities were 99.78% (95% confidence interval [95% CI]: 98.78–99.96), 99.12% (95% CI: 96.83–99.76), and 100% (95% CI: 88.30–100) for trisomies 21, 18, and 13, respectively. Specificities were more than 99.9% for trisomies 21, 18, and 13, respectively. Maternal age-specific PPVs were more than 93%, 77%, and 43% at the age of 35 years for trisomies 21, 18, and 13, respectively. Conclusion: The GeneTech NIPT data showed high sensitivity and specificity in the detection of fetal trisomies 21, 18, and 13 in high-risk pregnant women, and maternal age-specific PPVs were obtained. These results could provide more accurate and improved information regarding NIPT for genetic counseling in Japan.
AB - Aim: We aimed to evaluate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of noninvasive prenatal testing (NIPT) in high-risk pregnant women. Methods: Pregnant women who underwent GeneTech NIPT, the most commonly used NIPT in Japan, between January 2015 and March 2019, at Japan NIPT Consortium medical sites were recruited for this study. The exclusion criteria were as follows: pregnant women with missing survey items, multiple pregnancy/vanishing twins, chromosomal abnormalities in the fetus other than the NIPT target disease, and nonreportable NIPT results. Sensitivity and specificity were calculated from the obtained data, and maternal age-specific PPV and NPV were estimated. Results: Of the 45 504 cases, 44 263 cases fulfilling the study criteria were included. The mean maternal age and gestational weeks at the time of procedure were 38.5 years and 13.1 weeks, respectively. Sensitivities were 99.78% (95% confidence interval [95% CI]: 98.78–99.96), 99.12% (95% CI: 96.83–99.76), and 100% (95% CI: 88.30–100) for trisomies 21, 18, and 13, respectively. Specificities were more than 99.9% for trisomies 21, 18, and 13, respectively. Maternal age-specific PPVs were more than 93%, 77%, and 43% at the age of 35 years for trisomies 21, 18, and 13, respectively. Conclusion: The GeneTech NIPT data showed high sensitivity and specificity in the detection of fetal trisomies 21, 18, and 13 in high-risk pregnant women, and maternal age-specific PPVs were obtained. These results could provide more accurate and improved information regarding NIPT for genetic counseling in Japan.
KW - cell-free fetal DNA
KW - noninvasive prenatal testing
KW - prenatal diagnosis
KW - prenatal screening
KW - trisomy
UR - http://www.scopus.com/inward/record.url?scp=85112606501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112606501&partnerID=8YFLogxK
U2 - 10.1111/jog.14954
DO - 10.1111/jog.14954
M3 - Article
C2 - 34355471
AN - SCOPUS:85112606501
SN - 1341-8076
VL - 47
SP - 3437
EP - 3446
JO - Journal of Obstetrics and Gynaecology Research
JF - Journal of Obstetrics and Gynaecology Research
IS - 10
ER -